A képalkotó szerek egyszerre két rák biomarkert világítanak meg, hogy teljesebb képet adjanak a daganatról

05. június 2023. (Nanowerk News) A ráksebészek hamarosan teljesebb képet kaphatnak a daganatokról a műtét során, köszönhetően az új képalkotó szereknek, amelyek egyszerre több biomarkert is képesek megvilágítani – számoltak be az Illinois Egyetem Urbana-Champaign kutatói. A vörösvértestek membránjaiba burkolt fluoreszcens nanorészecskék jobban célozzák a daganatokat, mint a jelenlegi klinikailag jóváhagyott festékek, és két különböző jelet bocsátanak ki egyetlen műtéti fénysugárra válaszul, ami segíthet az orvosoknak megkülönböztetni a tumor határait és azonosítani a metasztatikus rákot. . A képalkotó szerek kombinálhatók bioinspirált kamerákkal, amelyeket a kutatók korábban a műtét során valós idejű diagnózishoz fejlesztettek ki – mondta Viktor Gruev, a kutatócsoport vezetője, az elektro- és számítástechnikai mérnök illinoisi professzora. A folyóirat új tanulmányában ACS Nano ("Cell-membrane coated nanoparticles for tumor delineation and qualitative estimation of cancer biomarkers at single wavelength excitation in murine and phantom models"), a kutatók új, kettős jelű nanorészecskéiket tumorfantomokban – a daganatok és környezetük jellemzőit utánzó 3D modellekben – és élő egerekben mutatták be. Researcher Indrajit Srivastava holds solutions of nanoparticles that can target two cancer biomarkers, giving off two distinct signals when lit by one fluorescent wavelength. This could give surgeons a more complete picture of a tumor and guide operating-room decisions. In the background is a microscopic scan of a tissue sample. (Image: Fred Zwicky) “If you want to find all the cancer, imaging one biomarker is not enough. It could miss some tumors. If you introduce a second or a third biomarker, the likelihood of removing all cancer cells increases, and the likelihood of a better outcome for the patients increases.” said Gruev, who also is a professor in the Carle Illinois College of Medicine. “Multiple-targeted drugs and imaging agents are a recent trend, and our group is driving the trend hard because we have the camera technology that can image multiple signals at once.” Traditionally, a surgeon removes a tumor and sends it to a pathologist for assessment, a process that can take hours to days, said Illinois postdoctoral researcher Indrajit Srivastava, the first author of the paper. As research has moved toward real-time diagnostics, several challenges have prevented wide application: Many tumor-targeted imaging agents only minimally reach their tumor targets, instead being quickly cleared from the blood stream and accumulating in the liver, Srivastava said. “A few people before us have used nanoparticles coated with red blood cells and found they circulate longer – a few days. We saw the same thing in our mice: The membrane-coated nanoparticles circulated longer in blood, with reduced uptake in the liver. Because they were circulating longer, more of the imaging agents accumulated in the tumors, giving us a stronger fluorescent signal,” Srivastava said. An artist’s rendering of membrane-wrapped nanoparticles binding to markers on a cancer cell and emitting colored light. The two biomarkers targeted by the new imaging agents include one that is prevalent in early cancer and one that is prevalent in late-stage cancer, which is more likely to be metastatic. The researchers found that the probes were effective at distinguishing cancerous tissue from healthy tissue, as well as distinguishing the two signals from each other. “This is appealing for surgical application, as it could help determine where exactly to make the cut. Having multiple signals gives a more overall picture of the tumor. And it could tell a surgeon, ‘This may be metastatic, you may want to be more aggressive in your removal.’” Srivastava said. Only needing one wavelength of laser light to elicit multiple signals is another benefit for surgical applications, as it makes the instrumentation much more compact than those requiring multiple lasers for each needed wavelength, Gruev said. The researchers plan to develop more tumor-imaging agents that target multiple markers, and to move forward with further preclinical and clinical studies using their dual-signal dyes with surgical goggles they have developed. “In this battle for ensuring we remove all the cancer cells during surgery, we need investments both in the imaging camera technology and in the tumor targeting agents,” Gruev said.

• SEO által támogatott tartalom és PR terjesztés. Erősödjön még ma.
• PlatoAiStream. Web3 adatintelligencia. Felerősített tudás. Hozzáférés itt.
• A jövő pénzverése – Adryenn Ashley. Hozzáférés itt.
• Részvények vásárlása és eladása PRE-IPO társaságokban a PREIPO® segítségével. Hozzáférés itt.
• Forrás: https://www.nanowerk.com/news2/biotech/newsid=63117.php